tetano
Editor, Senior Moderator
Eur Rev Med Pharmacol Sci
. 2020 Sep;24(18):9744-9747.
doi: 10.26355/eurrev_202009_23067.
The therapeutic potential of targeting ACE2 in COVID-19
R Elmorsi[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: ACE2 long served as the human gateway for multiple coronaviruses, including the currently pandemic SARS-CoV-2. This mini-review explores the potential of targeting ACE2 in blocking viral penetrance.
Materials and methods: PubMed search was conducted using the terms: "coronaviridae", "peptidyl-dipeptidase A", "ACE2", "SARS", and "SARS-CoV-2". References of relevant articles were further screened by the author.
Results: Four main methods of blocking ACE2-mediated viral penetrance were identified: receptor blockage, receptor decoying, receptor shedding, and co-receptor inhibition.
Conclusions: Drugs that inhibit viral binding to ACE2 present a strong choice for the current, and if necessary, future outbreaks. Further research is needed to establish the clinical and pharmacological aspects of the identified candidate molecules.
. 2020 Sep;24(18):9744-9747.
doi: 10.26355/eurrev_202009_23067.
The therapeutic potential of targeting ACE2 in COVID-19
R Elmorsi[SUP] 1 [/SUP]
Affiliations
- PMID: 33015820
- DOI: 10.26355/eurrev_202009_23067
Abstract
Objective: ACE2 long served as the human gateway for multiple coronaviruses, including the currently pandemic SARS-CoV-2. This mini-review explores the potential of targeting ACE2 in blocking viral penetrance.
Materials and methods: PubMed search was conducted using the terms: "coronaviridae", "peptidyl-dipeptidase A", "ACE2", "SARS", and "SARS-CoV-2". References of relevant articles were further screened by the author.
Results: Four main methods of blocking ACE2-mediated viral penetrance were identified: receptor blockage, receptor decoying, receptor shedding, and co-receptor inhibition.
Conclusions: Drugs that inhibit viral binding to ACE2 present a strong choice for the current, and if necessary, future outbreaks. Further research is needed to establish the clinical and pharmacological aspects of the identified candidate molecules.